New research exposes a systemic flaw in cryptocurrency media, finding that most press releases distributed through specialized wires promote dubious projects, blurring the lines between news and unvetted marketing.
Novo Nordisk stock plummeted nearly 17% following a stark forecast predicting a significant drop in 2026 sales and profit, driven by intense U.S. price pressures and rising competition in the lucrative GLP-1 drug market.
Disney's latest animated juggernaut isn't just a theatrical hit; it's a case study in how the company leverages blockbuster IP to drive growth across streaming, parks, and consumer products, creating a competitive moat that rivals struggle to breach.
Amid a strong start for major indices, a look at three lesser-known companies where recent insider buying activity hints at underlying value and management confidence.
While artificial intelligence reshapes the entry-level landscape, new data reveals that advanced degrees in human-centric fields like mental health counseling and law are not only resilient but experiencing surging demand, offering a clear path for graduates navigating economic uncertainty.
In an exclusive interview, Palantir Technologies CTO Shyam Sankar argues that the U.S. must urgently leverage AI to supercharge worker productivity and counter China's economic strategy, citing a case where factory yields jumped 50%.
A U.S. Senate investigation has revealed close to 900 previously hidden accounts at Credit Suisse with ties to Nazi organizations, shedding new light on the bank's wartime activities and raising fresh questions about historical accountability.
A generation of Venezuelan energy experts who fled political turmoil and helped build Canada's oil sands industry now see their future firmly rooted in their adopted country, despite recent geopolitical shifts aimed at reviving Venezuela's oil sector.
The U.S. Department of Defense has entered a seven-year agreement with Raytheon to dramatically increase output of key missiles, including Tomahawk cruise missiles and air-to-air interceptors, as part of a broader push to replenish inventories and bolster the defense industrial base.
Veteran investor Stanley Druckenmiller has made a significant portfolio shift, fully exiting Eli Lilly—a dominant player in the booming weight-loss drug market—while establishing new positions in three established tech giants betting on AI. The move raises questions about timing and strategy in two of today's hottest investment themes.
The AI boom is proving to be a double-edged sword for the technology sector. While some giants soar, a sharp selloff in software and services stocks highlights the market's growing discrimination between potential beneficiaries and those facing disruption from new AI tools.
As major indices rally on strong economic data, savvy investors are turning their attention to lesser-known companies with solid fundamentals. We analyze three small-cap stocks that combine financial resilience with attractive valuations in the current climate.
Michael Burry, the investor famed for predicting the 2008 financial crisis, warns that Bitcoin's sharp decline could trigger cascading liquidations and expose vulnerabilities in corporate treasuries and tokenized markets.
While IonQ captures headlines as a pure-play quantum computing stock, a deeper look reveals stronger investment opportunities lie with diversified tech titans who are building the quantum future on more stable foundations.
Weyerhaeuser (WY) shares have surged over 18% in the past three months, reigniting discussions about whether the timber and real estate investment trust remains undervalued or if the market is getting ahead of itself.
Recent volatility in Ipsos (ENXTPA:IPS) shares has investors questioning whether the stock's current price of €34.76 represents a buying opportunity, given a significant gap to some fair value estimates. We examine the data behind the valuation debate and the risks involved.
Regulatory milestones for two AstraZeneca cancer drugs—one in the U.S. and one in Europe—signal momentum for the pharma giant's targeted oncology pipeline, offering new hope for patients with difficult-to-treat cancers.
Analysts have raised their price target for school bus manufacturer Blue Bird (BLBD) to $76, signaling renewed optimism following better-than-expected quarterly results and a robust near-term forecast, even as the firm's core fair value estimate holds steady.
Shares of Pharming Group (ENXTAM:PHARM) came under pressure after the U.S. FDA issued a Complete Response Letter for its supplemental filing of Joenja in children with APDS. While the short-term sentiment turned negative, the company's longer-term growth trajectory and valuation gap present a complex picture for investors.
McKesson Corporation's stock has delivered staggering returns, climbing 374% over five years. As shares hover near record highs, analysts are divided: some see continued upside based on cash flow models, while others caution that the easy money may have been made. We examine the valuation debate surrounding this healthcare distribution behemoth.
